CF
IBB icon

Centaurus Financial’s iShares Biotechnology ETF IBB Stock Holding History

Centaurus Financial’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
944
+41
+5% +$7.05K 0.01% 926
2026
Q1 		$152K Buy
+903
New +$154K 0.01% 909
2024
Q3 		– Sell
-1,041
Closed -$143K – 855
2024
Q2 		$143K Sell
1,041
-8
-0.8% -$1.07K 0.01% 691
2024
Q1 		$144K Buy
1,049
+10
+1% +$1.37K 0.01% 688
2023
Q4 		$141K Sell
1,039
-224
-18% -$27.3K 0.01% 676
2023
Q3 		$154K Sell
1,263
-30
-2% -$3.81K 0.01% 634
2023
Q2 		$164K Sell
1,293
-931
-42% -$121K 0.01% 616
2023
Q1 		$287K Sell
2,224
-750
-25% -$98.2K 0.02% 553
2022
Q4 		$390K Buy
2,974
+1,181
+66% +$153K 0.04% 423
2022
Q3 		$210K Sell
1,793
-129
-7% -$16K 0.02% 606
2022
Q2 		$226K Buy
1,922
+237
+14% +$28.1K 0.02% 573
2022
Q1 		$220K Sell
1,685
-134
-7% -$17.5K 0.02% 638
2021
Q4 		$278K Sell
1,819
-655
-26% -$101K 0.02% 591
2021
Q3 		$400K Sell
2,474
-635
-20% -$107K 0.03% 475
2021
Q2 		$509K Buy
3,109
+1,667
+116% +$257K 0.04% 428
2021
Q1 		$217K Buy
1,442
+26
+2% +$4.13K 0.02% 577
2020
Q4 		$215K Sell
1,416
-135
-9% -$19.3K 0.02% 537
2020
Q3 		$210K Sell
1,551
-99
-6% -$13.4K 0.03% 442
2020
Q2 		$226K Buy
1,650
+7
+0.4% +$892 0.03% 397
2020
Q1 		$177K Sell
1,643
-1,961
-54% -$226K 0.04% 366
2019
Q4 		$434K Buy
3,604
+1,237
+52% +$138K 0.06% 332
2019
Q3 		$236K Buy
2,367
+545
+30% +$57K 0.04% 383
2019
Q2 		$199K Buy
1,822
+1,661
+1,032% +$177K 0.03% 423
2019
Q1 		$1.44K Buy
161
+16
+11% +$1.75K 0.01% 507
2018
Q4 		$2 Buy
145
+142
+4,733% +$15.1K 0.01% 407
2018
Q3 		$358 Sell
3
-4,077
-100% -$480K 0.06% 284
2018
Q2 		$448K Buy
4,080
+934
+30% +$99.9K 0.06% 327
2018
Q1 		$336K Buy
3,146
+233
+8% +$25.8K 0.08% 249
2017
Q4 		$311K Buy
+2,913
New +$311K 0.08% 238

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Centaurus Financial's IBB Position: Q2 2026 in Review

Centaurus Financial increased its iShares Biotechnology ETF (IBB) stake by 4.5% in Q2 2026, buying an estimated $7.05K and bringing the position to 944 shares worth $180K. The position accounts for 0.01% of the portfolio, ranked #926.

Centaurus Financial first reported a position in IBB in Q4 2017 and has held it in 29 quarters since. The position peaked at $509K in Q2 2021. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Centaurus Financial held 944 shares of iShares Biotechnology ETF worth $180K as of Q2 2026.
  • Centaurus Financial bought 41 iShares Biotechnology ETF shares in Q2 2026, an estimated $7.05K.
  • iShares Biotechnology ETF made up 0.01% of Centaurus Financial's portfolio in Q2 2026, its #926 holding.
  • Centaurus Financial first reported a position in iShares Biotechnology ETF in Q4 2017 and has held it in 29 quarters since.
  • Centaurus Financial's iShares Biotechnology ETF position peaked at $509K in Q2 2021.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.